NASDAQ:NOVN
Delisted
Novan, Inc. Stock News
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
10:30am, Monday, 16'th May 2022 GlobeNewswire Inc.
– Transformational quarter for Novan, marked by acquisition of EPI Health –
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
02:28pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
Basel, May 12, 2022 — Novartis highlights data from across its oncology portfolio at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Associa
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
01:00pm, Friday, 06'th May 2022 GlobeNewswire Inc.
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday,
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
09:00am, Friday, 06'th May 2022
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, Ma
New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
07:00am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
Basel, May 4, 2022 — Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in the first-line subgroup of postmenopausal wom
Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
10:00am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
Basel, April 27, 2022 — Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizum
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
05:00am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Novartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme
05:00am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Annonce événementielle selon l’art. 53 RC
Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten
05:00am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Ad-hoc-Mitteilung gemäss Art. 53 KR
Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
01:27pm, Friday, 22'nd Apr 2022 GlobeNewswire Inc.
Basel, April 22, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended gran
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right Now?
10:20am, Friday, 22'nd Apr 2022 Zacks Investment Research
Smart Beta ETF report for VIGI
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event
01:05pm, Wednesday, 20'th Apr 2022 GlobeNewswire Inc.
Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET Live moderated video webcast with members of the Novan management team on Tuesday, April 26t
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
05:15am, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
Basel, April 14, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
05:15am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Basel, April 6, 2022 — Sandoz today announces the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge dig
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
12:29am, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
Basel, April 6, 2022 — Novartis today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and pediatric patien
